glp 1 india pharma companies develop versions of Wegovy to get in on weight-loss windfall With GLP-1 drugs in the

When I trained, we were taught that weight was simple math: calories in minus calories out

This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)

[DOI] [PubMed] [Google Scholar] 4.Campbell J.N., Meyer R.A

3AH and Suppl